David T. Hagerty
2017
In 2017, David T. Hagerty earned a total compensation of $872.5K as Executive Vice President, Clinical Development at Conatus Pharmaceuticals, a 14% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $130,501 |
|---|---|
| Option Awards | $324,535 |
| Salary | $402,781 |
| Other | $14,646 |
| Total | $872,463 |
Hagerty received $402.8K in salary, accounting for 46% of the total pay in 2017.
Hagerty also received $130.5K in non-equity incentive plan, $324.5K in option awards and $14.6K in other compensation.
Rankings
In 2017, David T. Hagerty's compensation ranked 9,634th out of 14,666 executives tracked by ExecPay. In other words, Hagerty earned more than 34.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 9,634 out of 14,666 | 34th |
Division Manufacturing | 3,713 out of 5,772 | 36th |
Major group Chemicals And Allied Products | 1,286 out of 2,075 | 38th |
Industry group Drugs | 1,035 out of 1,731 | 40th |
Industry Pharmaceutical Preparations | 815 out of 1,333 | 39th |
Source: SEC filing on April 27, 2018.
Hagerty's colleagues
We found two more compensation records of executives who worked with David T. Hagerty at Conatus Pharmaceuticals in 2017.